NCT06037876View on ClinicalTrials.gov

Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura

PHASE3CompletedINTERVENTIONAL

Enrollment

161

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

November 9, 2023

Study Completion Date

November 14, 2023

Conditions

Trichuriasis

Interventions

DRUG

IVM (200 µg/kg) + ALB (400 mg)

World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.

DRUG

ALB (400mg)

Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO

Trial Locations (1)

P.O.Box 1661

Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health, Kampala

All Listed Sponsors

collaborator

Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health, Uganda

UNKNOWN

lead

Jennifer Keiser

OTHER

NCT06037876 - Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura | Biotech Hunter | Biotech Hunter